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Abstract
Objective Patients with hypoparathyroidism exhibit metabol-
ic disorders (hypocalcemia) and brain structural abnormalities
(brain calcifications). Currently, studies have determined
whether antiepileptic drug (AED) treatment is required for
epileptic seizures in children with hypoparathyroidism.
Method This study aims to evaluate the data of two medical
centers in Beijing based on the diagnosis of epileptic seizures
as the first symptom of hypoparathyroidism in children.
Result A total of 42 patients were included and assigned into
AED and non-AED treatment groups in a 1:2 matched case–
control study. Results show that the seizure outcome after
1 year of AED treatment is not significantly different from
that of the control. In the subgroup analysis of patients with
subcortical calcifications, the seizure outcome is still not sig-
nificantly different from that of the control.
Conclusion Thus, AED treatment cannot improve the seizure
outcomes in children with parathyroid disorder, even in such
cases as suspected structural seizure caused by subcortical calci-
fications. Clinicians must take adequate considerations on the use
of AEDs in these patients. Epileptic seizures, as the first symptom
of hypoparathyroidism in children, do not require epilepsy drugs.
Keywords Epilepsy . Parathyroid . Intracranial calcification .
Hypocalcemia
Introduction
Epileptic seizure occurs when a burst of electrical impulses in
the brain exceeds the normal limits. Its manifestation can vary
from uncontrolled jerking movement (tonic–clonic seizure) to
momentary loss of awareness (absence seizure). These im-
pulses spread to adjacent areas in the brain and create an un-
controlled storm of electrical activity. Brain diseases character-
ized by enduring predisposition to generate epileptic seizures
are collectively called epilepsy. According to pathogenesis, ep-
ilepsy can be classified into six categories: metabolic, structural,
inherited, immunologic, inflammatory, and idiopathic.
Hypoparathyroidism is an endocrine disease that results
from parathyroid hormone (PTH) deficiency or any resistance
to its hormonal function, and manifestations of this disease
mainly include hypocalcemia, hyperphosphatemia, and ab-
normal PTH serum level [1]. Seizures in patients diagnosed
with hypoparathyroidism are ascribed to a calcium phospho-
rus metabolism disorder. In addition, parathyroid disorders are
usually accompanied by intracranial calcifications, which oc-
cur in 21.5 to 73% of patients with hypoparathyroidism; these
observations are recognized as long-term complications of
hypocalcemia [2]. Hypocalcemia can lead to reduced excitato-
ry threshold, increased neural transmission, and increased
neuromuscular excitation [3]. This condition can also lead to
the increased susceptibility of hippocampal neurons to epilep-
sy and can impair the cerebral function through
encephaledema, increased intracranial pressure, andmetabolic
disorder [4]. In this case, a sole treatment with antiepileptic
drugs (AEDs) is insufficient. Combining calcium supplements
and AEDs is necessary to produce the optimal outcome in
patients with epilepsy. Meanwhile, structural etiology refers
to lesions in the brain, including intracranial calcifications.
The probability of intracranial calcification occurrence is ap-
proximately 0.36/12,000. In the studies on Sturge–Weber
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syndrome, intracranial calcification is thought to be closely
related to the severity of epilepsy [5]. Other studies demon-
strated that the location of subcortical calcification corre-
sponds to that of the epileptic discharge and that the severity
of epilepsy is related to gliosis around the calcification [6, 7].
For epilepsy caused by intracranial calcification, the use of
AEDs remains controversial among clinicians. Moreover, few
studies with large sample size have been conducted to address
this problem, and most of the related studies available now are
case reports. We retrospectively reviewed the information
from two medical centers in Beijing to address this problem
and to provide guidance to clinicians.
Method
We retrospectively reviewed 42 patients diagnosed with para-
thyroid disorders who exhibited epileptic seizure as a first
symptom. These patients were introduced in the pediatric de-
partments of PLA General Hospital and Beijing Children’s
Hospital from 2001 to 2015. Considering that the main out-
come is the prognosis after treatment with AEDs for 1 year
and both groups (AED group and non-AED group) received
calcium supplement therapy, we conducted a 1:2 matched
case–control study by length of the course and calcium sup-
plement therapy. The ethics committees of the participating
institutions approved this study.
The diagnosis of parathyroid disorders was conducted
through blood and urine calcium phosphorus metabolism
and PTH serum level tests. Other inclusion criteria were as
follows: all the patients underwent CT scan and EEG test, and
the results showed existence of intracranial calcifications, the
first manifestation was recurrent seizures, and all the patients
had received calcium supplement therapy, and the dosage ad-
justment was made through blood calcium level monitoring.
Patient flow and AED regimen are shown in Fig. 1.
Fig. 1 Participant flow
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The variables that we collected include sex, results of CT
scan, EEG results, use of AEDs, type of parathyroid disorders,
Chvostek’s sign, Trousseau’s sign, and calcium phosphorus
metabolism test results.
Statistical analysis
All analyses were performedwith SPSS 19.0. The paired-sample
t test was used for the comparison of the continuous variables.
For categorical variables, univariate conditional logistic regres-
sion was used to determine the odds ratio (OR). A probability
value of P < 0.05 was considered statistically significant. The
ORs and 95 % confidence intervals (95 % CIs) were presented.
Results
Patient characteristics
As shown in Fig. 1, 42 of the 120 patients with parathyroid
disorders satisfied the criteria. They were divided into the
AED treatment and non-AED treatment groups in a 1:2
matched case–control approach. The characteristics of the 42
patients are shown in Table 1. Generally, 22 (52.38 %) of the
patients are males, and 20 (47.62%) are females. The mean age
at the onset is 7.55 (1 month to 16 years old). Furthermore, 25
(59.52 %) and 17 (40.48 %) patients were diagnosed with hy-
poparathyroidism and pseudohypoparathyroidism, respective-
ly. The seizures lasted from several seconds to around 30 min,
as shown in Table 2, and most of the seizures exhibited convul-
sions (hypoparathyroidism 72 %, pseudo-hypoparathyroidism
58.8 %). Relatively few tetany episodes were observed
(hypoparathyroidism, 20 %; pseudohypoparathyroidism,
11.8%). However, numbness, dizziness, and absence were rare.
Incidence of mental retardation was observed in 24 and 11.8 %
o f t h e pa t i e n t s w i t h hypopa r a t hy r o i d i sm and
pseudohypoparathyriodism, respectively. Patients with
Albright’s hereditary osteodystrophy exhibit a rounded face,
short stature, mild mental retardation, and brachydactylia.
These cases composed 23.5 % of the patients with pseudo-
hypoparathyroidism. Incidence of QT interval prolongation
was 40 % in hypoparathyroidism and 42.9 % in
pseudohypoparathyroidism. No ectopic calcifications were ob-
served through ultrasound. Calcium level varied from 1.13 to
2.37 mmol/L (1.61 ± 0.27 mmol/L). Serum PTH level of hy-
poparathyroidism varied from 1 to 59.18 pg/mL
(12.28 ± 17.59 pg/mL); the level of pseudohypoparathyroidism
varied from 99.39 to 868.00 pg/mL (436.10 ± 262.56 pg/mL).
The alkaline phosphatase levels varied from 72 to 2094 IU/L.
The EEG results were normal in 19 (45.24 %) patients and
abnormal in 23 (54.76 %) patients; 29 (69.05 %) patients have
subcortical calcification. Finally, Chvostek’s sign was positive
in 22 (52.38 %) patients; likewise, Trousseau’s sign was posi-
tive in 13 (30.95 %) patients.
Effect of AEDs on seizures
The patients received different AEDs, such as levetiracetam
(four patients), phenobarbital (two patients), carbamazepine
(three patients), valproate (three patients), topiramate (two pa-
tients), and oxcarbazepine (two patients). Most of the patients
underwent one-drug therapy; only two patients had their
AEDs changed. One patient replaced carbamazepine with le-
vetiracetam because of an allergy.
The results of univariate analysis are shown in Table 3. No
significant differences were found in the variables between the
AED and the non-AED treatment groups (sex, P = 0.82,
OR = 1.64, 95 % CI = 0.31–4.40; serum calcium level,
Table 1 Demographics and symptoms
n = 42
Sex
Male/female 22 (52.38 %)/20 (47.62 %)
Age of onset (years) 7.55 ± 5.21
Type of parathyroid disorders
Primary 25 (59.52 %)
Pseudo 17 (40.48 %)
CT scan
Subcortical zone calcification 29 (69.05 %)
Non-subcortical zone calcification 13 (30.95 %)
Chvostek’s sign
Positive/negative 22 (52.38 %)/20 (47.62 %)
Trousseau’s sign
Positive/negative 13 (30.95 %)/29 (69.05 %)
Results of EEG
Normal/abnormal 19 (45.24 %)/23 (54.76 %)
Age of onset was shown as means ± SD; others were shown as n (%)
Table 2 Detailed description of seizures
Manifestations Hypoparathyroidism Pseudohypoparathyroidism
Mental retardation 6/25 (24 %) 2/17 (11.8 %)
Convulsions 18/25 (72 %) 10/17 (58.8 %)
Tetany 5/25 (20 %) 2/15 (11.8 %)
Numbness 1/25 (0.04 %) 0/17 (0 %)
Dizziness 0/25 (0 %) 1/17 (5.9 %)
Absence 0/25 (0 %) 1/17 (5.9 %)
AHO symptoms 0/25 (0 %) 4/17 (23.5 %)
QT interval
prolongation
6/15 (40 %) 3/7 (42.9 %)
AHO: patients with this disorder are mainly manifested with short stature,
characteristically shortened fourth and fifth metacarpals, rounded facies,
and often mild mental retardation
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P = 0.76, OR = 1.99, 95 % CI = 0.03–158.80; results of EEG,
P = 0.05, OR = 3.79, 95 % CI = 0.98–14.67; type of parathyroid
disorders, P = 0.33, OR = 0.54, 95 % CI = 0.16–1.87; age of
onset, P = 0.15, OR = 0.92, 95 % CI = 0.82–1.03; type of
seizures, P = 0.62, OR = 0.69, 95 % CI = 0.16–3.05; results of
CTscan, P = 0.66, OR = 1.34, 95% CI = 0.37–4.93; Chvostek’s
sign, P = 0.85, OR = 1.12, 95 % CI 0.35–3.57; and Trousseau’s
sign, P = 0.81, OR = 1.18, 95 % CI = 0.29–4.76).
As shown in Fig. 2 and Table 3, no significant differences
were observed between the seizure outcomes after AED treat-
ment and those of the controls for 1 year (P = 0.34,
OR = 169.48, 95.0 % CI = 0.00–6,403,719.35). The seizure-
free rates were 78.57 and 53.57 % in the AED and non-AED
treatment groups, respectively. The therapeutic effect on a
patient is shown in Fig. 3. The EEG result was significantly
ameliorated after calcium supplement therapy for less than
1 week, and a seizure-free outcome was attained, and no re-
currence was observed.
To confirm the necessity of AED use in patients with sub-
cortical calcification, we subdivided the patients into AED
and non-AED treatment groups before their seizure outcomes
were compared as described previously, but with the patients
matched at 1:1.
No significant differences were observed among all the
observed variables (sex, P = 0.66, OR = 0.67, 95 %
CI = 0.11–4.00; serum calcium level, P = 1, OR = 1, 95 %
CI = 0.00–28,737.39; results of EEG, P = 0.22, OR = 4, 95 %
CI = 0.45–35.79; type of parathyroid disorders, P = 0.42,
OR = 0.5, 95 % CI = 0.09–2.73; age of onset, P = 0.47,
OR = 0.95, 95 % CI = 0.81–1.10; type of seizures, P = 1,
OR = 1, 95 % CI = 0.14–7.10; Chvostek’s sign, P = 1,
OR = 1, 95 % CI = 0.20–4.96; Trousseau’s sign, P = 0.66,
OR = 0.67, 95 % CI = 0.11–4.00).
In addition, the seizure outcomes were not different from
the controls, as shown in Fig. 4 and Table 4 (P = 0.38,
OR = 0.02, 95 % CI = 0.00–164.78). Seizure-free rates were
66.67 % in the AED and non-AED treatment groups.
Subcortical calcifications and EEG findings and seizures
The incidence of frontal lobe calcification is the highest
among all subcortical calcifications. In our study, only 6 pa-
tients had frontal lobe calcifications, 19 patients had subcorti-
cal calcifications in their frontal lobes and other sites, and 3
patients had no frontal lobe calcification. These findings indi-
cated that the incidence of frontal lobe calcification is 89.3 %.
In addition, the relationship between the EEG and the CT
scan results is shown below: the ratio of the abnormal/normal
Table 3 Characteristics of 42 subjects divided into two groups according to use of AEDs
Factors Treatment with AEDs Treatment without AEDs OR (95 % CI) P value (two sided)
Sex 1.64 (0.31–4.40) 0.82
Male/female 7/7 15/13
Serum calcium level (means ± SD) 1.59 ± 0.17 1.62 ± 0.32 1.99 (0.03–158.80) 0.76
Results of EEG 3.79 (0.98–14.67) 0.05
Normal/abnormal 3/11 16/12
Type of parathyroid disorders 0.54 (0.16–1.87) 0.33
Hypoparathyroidism/pseudohypoparathyroidism 10/4 15/13
Age of onset (means ± SD) 5.72 ± 6.03 8.47 ± 4.60 0.92 (0.82–1.03) 0.15
Type of seizures 0.69 (0.16–3.05) 0.62
Focal/generalized 6/4 12/12
Results of CT scan 1.34 (0.37–4.93) 0.66
Subcortical calcification 9 20
No subcortical calcification 5 8
Chvostek’s sign 1.12 (0.35–3.57) 0.85
Positive/negative 7/7 15/13
Trousseau’s sign 1.18 (0.29–4.76) 0.81
Positive/negative 4/10 9/19
Conditional logistic regression was used for comparison
Fig. 2 Seizure outcome is not significantly different between the subjects
with AED treatment and those without AED treatment, P = 0.34
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EEG findings is 50 % in the case with only basal ganglia
calcifications. This result is consistent with the conclusion that
abnormal EEG findings are not associated with basal ganglia
calcifications [8]. The ratio is reduced to 20% in the case with
only frontal lobe calcifications, and 50 % ratio was observed
in the case with subcortical calcifications except in the frontal
lobe. The ratio is 55 % in cases with subcortical calcifications
in the frontal lobe and other sites. The result is shown in Fig. 5.
In the results of the chi-square test, the type of seizure was
not significantly associated with either the subcortical calcifi-
cations or the EEG findings (subcortical calcifications and
type of seizures, P = 0.477; EEG findings and type of seizures,
P = 0.732). In addition, the type of seizures did not change
significantly regardless of the existence of frontal lobe calci-
fications (Fig. 5).
Calcium level and seizure outcome
The outcomes of seizure control were evaluated in all the
untreated patients according to calcium normalization. A
matched case–control comparison was performed by sex and
duration of disease. The seizure control outcome was evaluat-
ed when calcium normalization occurred. The results sug-
gested that the rate of seizure control was relatively high in
patients with calcium normalization (P = 0.006; Fig. 6).
Fig. 3 The EEG results of a patient with pseudohypoparathyroidism
before (a, b) and after (c, d) calcium supplement therapy. Before
treatment, the EEG shows suspicious epileptic discharge characterized
by spike wave and multiple spike waves. After treatment, the epileptic
discharge is obviously ameliorated and the patient has reached seizure-
free state
Fig. 4 In the subjects with subcortical calcifications, seizure outcome is
not significantly different in subjects with AED treatment and those
without AED treatment, P = 0.38
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Intracranial calcifications and seizure features
and outcomes
Among the 120 patients, we selected the patients with calcifi-
cations at different sites to compare their seizure features and
seizure control outcomes.
As shown in Table 5, no significant difference can be ob-
served among the seizure durations (calcification, 3.86 ± 5.50
with n = 43 vs. no calcification, 10.72 ± 28.68 with n = 17;
P = 0.341). However, the seizure frequency was relatively
high (calcification, 597.55 ± 964.08 with n = 22 vs. no calci-
fication, 1654.00 ± 1290.34 with n = 11; P = 0.013). The
Table 4 Characteristics of subjects with subcortical calcifications divided into two groups according to use of AEDs
Factor Treatment with AEDs Treatment without AEDs OR (95 % CI) P value (two sided)
Sex 0.67 (0.11–4.00) 0.66
Male/female 6/3 5/4
Serum calcium level (means ± SD) 1.60 ± 0.22 1.79 ± 0.41 1 (0.00–28,737.39) 1
Results of EEG 4 (0.45–35.79) 0.22
Normal/abnormal 2/7 5/4
Type of parathyroid disorders 0.5 (0.09–2.730 0.42
Hypoparathyroidism /pseudohypoparathyroidism 6/3 4/5
Age of onset (means ± SD) 4.59 ± 5.49 6.78 ± 5.27 0.95 (0.81–1.10) 0.47
Type of seizures 1 (0.14–7.10) 1
Focal/generalized 3/3 4/5
Chvostek’s sign 1 (0.20–4.96) 1
Positive/negative 4/5 4/5
Trousseau’s sign 0.67 (0.11–4.00) 0.66
Positive/negative 3/6 2/7
Conditional logistic regression was used for comparison
Fig. 5 Relationship among results of CTscan and EEG findings and type
of seizures. No significant association was observed (a sites of
calcifications × EEG, P value not available; b with or without
subcortical calcifications × type of seizures, P = 0.477; c with or
without frontal lobe calcifications × type of seizures, P = 0.648; d EEG
findings × type of seizures, P = 0.732)
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duration since first seizure was relatively short (calcification,
5.67 ± 8.18 with n = 73 vs. no calcification, 1.17 ± 2.29 with
n = 31; P = 0.00) in the no-calcification group.
As shown in Table 6, no significant difference was present
between the multiple calcification group and the single calcifi-
cation group with respect to seizure duration (multiple calcifica-
tions, 2.70 ± 2.92with n = 29 vs. single calcification, 6.24 ± 8.38
with n = 14; P = 0.147), seizure frequency (multiple calcifica-
tions, 643.87 ± 1049.21 with n = 13 vs. single calcification,
530.64 ± 883.21 with n = 9; P = 0.794), and duration since the
first seizure (multiple calcifications, 5.66 ± 8.59 with n = 55 vs.
single calcification, 5.68 ± 7.01 with n = 18; P = 0.995).
As shown in Table 7, there was no significant difference
with respect to seizure duration (only basal ganglion calcifi-
cation, 6.03 ± 9.03 vs. no calcification, 10.72 ± 28.64;
P = 0.59) and frequency (only basal ganglion calcification,
528.59 ± 944.17 vs. no calcification, 1654.00 ± 1290.34;
P = 0.052) between the basal ganglion calcification group
(n = 16) and the no-calcification group (n = 31). Duration
since first seizure was relatively short in the no-calcification
group (only basal ganglion calcification 4.95 ± 6.40 vs. no
calcification, 1.17 ± 2.29; P = 0.035).
Discussion
Clinical seizures are present in about two thirds of idiopathic
hypoparathyroidism incidence. Their symptoms vary from
circumoral numbness, muscle cramps, paresthesias of the hands
and feet, to generalized tonic–clonic seizures. Seizures can be
induced by hypocalcemia or intracranial calcifications, but wheth-
er these seizures are epilepsy or tetany cannot be determined from
the clinical manifestations alone. To clarify the type of seizures,
we must evaluate the EEG to determine whether epileptic dis-
charges are present; calcium supplement therapy should also con-
firm whether seizures respond to this treatment [9].
According to our results, as the first symptom of hypopara-
thyroidism in children, epileptic seizures were not evidently
improved by administering AED treatment to calcium supple-
ment therapy.
Even in the presence of cortical calcifications, which could
be suspected as a cause of structural epilepsy, AEDs did not
significantly improve the seizure outcome. This finding can be
explained as follows: the manifestations of parathyroid disor-
ders were mainly caused by calcium phosphorus metabolic
disorders, and the intracranial calcifications were metastatic
calcifications (calcifications that occurred due to hypocalce-
mia but not due to intracranial lesion). Treatment of these
diseases must focus on calcium supplementation and not on
the invalid AED therapy. Our results are consistent with the
study of Modi et al. [10], who indicated that patients with
hypoparathyroidism could reach optimal seizure outcomes re-
gardless of the use of AEDs. Although adult patients were
included in their study, patients with seizures as the first man-
ifestation were mainly in their childhood; this trend was sim-
ilar among our included patients.
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Fig. 6 Seizure control outcomes in untreated patients with or without
normalization of calcium






















Table 7 Comparison of seizure features between patients with basal
ganglion calcification and patients without calcification
Only basal ganglion
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Childs Nerv Syst (2017) 33:297–305 303
Serum calcium levels are low in patients with or without
AED treatment so these factors could trigger seizures. The
baselines of the two groups are not significantly different from
each other, including the serum calcium. Therefore, the state-
ment that the seizure control outcome does not have statistical
or clinical significance is reasonable.
Among the varied follow-up durations of all the patients in
this study, we chose the 1-year follow-up because the start of
the AED treatment was used as reference to evaluate the effi-
cacy of AEDs on seizure control. Runge [11] evaluated the
effectiveness of lacosamide for almost 6 months since its ad-
dition to therapy. Hussain [12] evaluated the effectiveness of
cannabidiol (CBD) as an add-on therapy for patients with
infantile spasms (IS) or Lennox–Gastaut (G) syndrome at
∼6.8 months after medication started. Chen [13] evaluated
the efficacy of levetiracetam in patients with electrical status
epilepticus in sleep (ESES); the follow-up duration was used
as inclusion criteria because his study started no less than
1 year since patient medication. Thus, 1-year-long follow-up
is enough to determine the effectiveness of AED on seizure
control in this study.
Cortical calcifications mainly occur in the frontal lobe.
Moreover, EEG findings are not associated with the type of
seizures, thereby supporting our conclusion previously. The
rate of abnormal EEG findings is relatively low when only the
subcortical calcifications are present in the frontal lobe or the
other sites because of the small sample size and the false-
negative rate of EEG. As referenced previously, discrepancies
exist on the relation between the subcortical calcification and
the abnormal EEG findings, and numerous studies are limited
to a certain disease (for example, brain cysticercosis and
Sturge–Weber syndrome) [5–7, 14]. Our sample size is small,
and this study is just a preliminary exploration of this problem
in parathyroid disorders.
Serum calcium levels are lower in patients with AED treat-
ment. In addition, most patients were taking one of the follow-
ing AEDs: phenobarbital, carbamazepine, or valproic acid so-
dium; these AEDs are detrimental to calcium levels and patient
prognosis [15]. These results suggest that the use of AEDsmust
be carefully considered in patients with parathyroid disorders
because these drugs could be ineffective or even detrimental.
Given that some of the detailed EEG results cannot be
obtained in our patients, the analysis of a detailed EEG de-
scription is not listed previously. However, according to our
data, the description of EEG is consistent with previous pub-
lications, thereby indicating that the abnormalities in the EEG
are characterized by slow theta and delta waves, spike-wave
discharges that vary in frequency from 1.5 c/s to 4 c/s, and
single and multiple spiking [16].
By excluding the effect of AED therapy, calcium normali-
zation facilitated seizure control in all the patients without
AED treatment. This result confirmed the nature of hypopara-
thyroidism as a metabolic disorder and supports the finding
that AED treatment cannot improve the seizure control
outcome.
As reported in a previous study [17], 21.5 to 73 % of the
patients showed intracranial calcifications. The intracranial cal-
cification rate of 76.9 % in patients with poorly controlled cal-
cium levels must be extremely high (Fig. 7), thereby indicating
that calcification is associated with long-term poorly controlled
calcium. Almost half of the patients with poorly controlled cal-
cium levels did not achieve seizure control. This trend is con-
sistent with the rate of seizure control in patients without AED
treatment and calcium normalization (Fig. 6).
Patients with calcification showed relatively long seizure
durations since the first seizure. As shown in Tables 5 and 7,
the duration since the first seizure is relatively long in patients
with calcifications. In Table 6, both groups have intracranial
calcifications and the duration was not significantly different
since the first seizure was observed. This finding is consistent
with the statement that calcification is a long-term complica-
tion in disorders of calcium phosphorus metabolism [17].
Basal ganglion calcification is not associated with epileptic
discharges [8]. No significant differences were observed when
the seizure features were compared between patients with only
basal ganglion calcification and patients without calcification,
except in the duration since the first seizure.
Consistent conclusions cannot be formulated by comparing
the seizure frequencies between calcification and no-
calcification groups, as well as between multiple calcification
and single calcification groups. In the multiple calcification
group and calcification group, calcification in the different
sites probably had varying effects on epileptic discharges.
Except for these confounding factors, the sample size of these
comparisons is small. Thus, further investigation is required
for more conclusive results.
This work is a retrospective study with a small sample size.
Therefore, selection bias may exist. Large-sample prospective
studies are necessary to elucidate the necessity of administer-
ing AEDs in parathyroid disorders.
Fig. 7 Intracranial calcifications in patients with poorly controlled
calcium
304 Childs Nerv Syst (2017) 33:297–305
Compliance with ethical standards The ethics committees of the par-
ticipating institutions approved this study.
Conflict of interest We declare that there is no conflicts of interest.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Michels TC, Kelly KM (2013) Parathyroid disorders. Am Fam
Physician 88(4):249–257
2. Hao D, Wen Z, Jankovic J (2015) Genetics and molecular biology
of brain calcification. Ageing Res Rev 22:20–38
3. Gambardella A, Labate A (2014) The role of calcium channel mu-
tations in human epilepsy. Prog Brain Res 213:87–96
4. Wang G et al (2015) CaV3.2 calcium channels control NMDA
receptor-mediated transmission: a new mechanism for absence ep-
ilepsy. Genes Dev 29(14):1535–1551
5. Wu J et al (2011) Cortical calcification in Sturge-Weber syndrome
onMRI-SWI: relation to brain perfusion status and seizure severity.
J Magn Reson Imaging 34(4):791–798
6. Singh G et al (2000) Focal cortical-subcortical calcifications
(FCSCs) and epilepsy in the Indian subcontinent. Epilepsia 41(6):
718–726
7. Agarwal A et al (2004) Epilepsy with focal cerebral calcification:
role of magnetization transfer MR imaging. Neurol India 52(2):
197–199
8. Aggarwal S et al (2013) Neuropsychological dysfunction in idio-
pathic hypoparathyroidism and its relationship with intracranial cal-
cification and serum total calcium. Eur J Endocrinol 168(6):895–
903
9. Bedoin N et al (2006) Hemispheric lateralization of cognitive func-
tions in children with centrotemporal spikes. Epilepsy Behav 9(2):
268–274
10. Modi S et al (2014) Seizures in patients with idiopathic hypopara-
thyroidism: effect of antiepileptic drug withdrawal on recurrence of
seizures and serum calcium control. Eur J Endocrinol 170(5):777–
783
11. Runge U et al (2015) A noninterventional study evaluating the
effectiveness and safety of lacosamide added to monotherapy in
patients with epilepsy with partial-onset seizures in daily clinical
practice: the VITOBA study. Epilepsia 56(12):1921–1930
12. Hussain SA et al (2015) Perceived efficacy of cannabidiol-enriched
cannabis extracts for treatment of pediatric epilepsy: a potential role
for infantile spasms and Lennox–Gastaut syndrome. Epilepsy &
Behavior E & B 13(1):1–7
13. Chen J et al (2015) Levetiracetam efficacy in children with epilepsy
with electrical status epilepticus in sleep. Epilepsy Behav 44C:73–77
14. Cronin CC et al (1998) Coeliac disease and epilepsy. QJM 91(4):
303–308
15. Valsamis HA et al (2006) Antiepileptic drugs and bonemetabolism.
Nutr Metab (Lond) 3:36
16. Glaser GH, Levy L (1960) Seizures and idiopathic hypoparathy-
roidism. A clinical-electroencephalographic study. Epilepsia 1:
454–465
17. Deng H, Zheng W, Jankovic J (2015) Genetics and molecular biol-
ogy of brain calcification. Ageing Res Rev 22:20–38
Childs Nerv Syst (2017) 33:297–305 305
